NSUP
CRSP icon

NLB Skladi upravljanje premozenja’s CRISPR Therapeutics CRSP Stock Holding History

NLB Skladi upravljanje premozenja’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$606K Hold
11,111
– – 0.02% 288
2026
Q1 		$529K Buy
11,111
+1,111
+11% +$58.6K 0.03% 276
2025
Q4 		$524K Buy
+10,000
New +$599K 0.02% 276

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

NLB Skladi upravljanje premozenja's CRSP Position: Q2 2026 in Review

NLB Skladi upravljanje premozenja held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 11,111 shares worth $606K. The position accounts for 0.02% of the portfolio, ranked #288.

NLB Skladi upravljanje premozenja first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • NLB Skladi upravljanje premozenja held 11,111 shares of CRISPR Therapeutics worth $606K as of Q2 2026.
  • NLB Skladi upravljanje premozenja left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 0.02% of NLB Skladi upravljanje premozenja's portfolio in Q2 2026, its #288 holding.
  • NLB Skladi upravljanje premozenja first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on NLB Skladi upravljanje premozenja's 13F filing for Q2 2026, filed 6 Aug 2026.